Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Sep-Oct;17(5):587-595.
doi: 10.21873/cgp.20215.

Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes

Anca Nastase  1 , Audrey Lupo  2 , Victoria Laszlo  1 , Diane Damotte  2 , Simona Dima  1 , Emelyne Canny  2 , Marco Alifano  2 , Irinel Popescu  1 , Walter Klepetko  3 , Madalina Grigoroiu  4
Affiliations
Observational Study

Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes

Anca Nastase et al. Cancer Genomics Proteomics. 2020 Sep-Oct.

Abstract

Background/aim: Patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) with no progression after induction chemotherapy are usually selected for surgery. Nowadays, response to chemotherapy is not predictable. We aimed to identify genomic predictive markers for response to induction chemotherapy in stage IIIA (N2) NSCLC patients.

Patients and methods: Whole-exome sequencing (WES) was performed on samples from 11 patients with no response after induction chemotherapy and 6 patients with documented pathological response, admitted to the Hotel Dieu Hospital, Paris or Allegemeines Krakenhaus University, Vienna.

Results: A higher alternative allele frequency was found on SENP5, rs63736860, rs1602 and NCBP2, rs553783 in the non-responder group, and on RGP1, rs1570248, SLFN12L, rs2304968, rs9905892, and GBA2, rs3833700 in the responder group.

Conclusion: These polymorphisms contribute to inter-individual sensibility to chemotherapy response. Interrogation of these genetic variations may have potential applicability when deciding the treatment strategy for patients with stage III NSCLC (N2).

Keywords: NSCLC; Whole-exome sequencing; platinum sensitivity.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. (A) Study workflow showing number of patients in each group and exclusion reasons. (B) Diagram showing patient distribution in response groups, type of response to treatment and gender (http://sankeymatic.com).
Figure 2
Figure 2. Analysis of SNPs associated with response: (A) Graphical representation of the seven SNPs identified and their location on chromosomes and genes (graph sizes do not take into account real sizes); (B) Forest plot of top 5 five genes altered between Group A (non-responders) and Group B (responders) at p<0.01; (C) Alternative allele frequency of the statistically significant SNPs (p<0.01) between non-responders (Group A) and responders (Group B).
Figure 2
Figure 2. Analysis of SNPs associated with response: (A) Graphical representation of the seven SNPs identified and their location on chromosomes and genes (graph sizes do not take into account real sizes); (B) Forest plot of top 5 five genes altered between Group A (non-responders) and Group B (responders) at p<0.01; (C) Alternative allele frequency of the statistically significant SNPs (p<0.01) between non-responders (Group A) and responders (Group B).
Figure 3
Figure 3. Heatmap matrix of pairwise linkage disequilibrium in 5 European populations for SNPs on chromosome 3 (A); chromosome 9 (B) and chromosome 17 (C) (heatmaps and D’ and R2 were generated using the LDmatrix module from LDlink (6); the shade of red represents the degree of linkage disequilibrium between the pairs.
See this image and copyright information in PMC

References

    1. Wood DE. National comprehensive cancer network (NCCN) clinical practice guidelines for lung cancer screening. Thorac Surg Clin. 2015;25(2):185–197. doi: 10.1016/j.thorsurg.2014.12.003. - DOI - PubMed
    1. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Ozguroglu M, Antonia SJ. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from pacific. J Thorac Oncol. 2020;15(2):288–293. doi: 10.1016/j.jtho.2019.10.002. - DOI - PMC - PubMed
    1. Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of veterans health administration data. J Thorac Oncol. 2014;9(5):702–709. doi: 10.1097/JTO.0000000000000146. - DOI - PMC - PubMed
    1. Goodsell DS. The molecular perspective: Cisplatin. Oncologist. 2006;11(3):316–317. doi: 10.1634/theoncologist.11-3-316. - DOI - PubMed
    1. Grigoroiu M, Tagett R, Draghici S, Dima S, Nastase A, Florea R, Sorop A, Ilie V, Bacalbasa N, Tica V, Laszlo V, Mansuet-Lupo A, Damotte D, Klepetko W, Popescu I, Regnard JF. Gene-expression profiling in non-small cell lung cancer with invasion of mediastinal lymph nodes for prognosis evaluation. Cancer Genomics Proteomics. 2015;12(5):231–242. - PubMed

Publication types

MeSH terms